Daily Summary of Health · Live edition, updated continuouslyTuesday 10 November 2026 · UTC
Latest Health News Today: 10 November 2026
MND therapy enters Phase 2 as phage protein study points to antibiotics
An Australian-developed MND therapy will enter a 75-person Phase 2 trial, aiming to halt or reverse disease progression. A phage protein study identified a shared way of blocking the bacterial target MurJ, offering clues for future antibiotics. A UCLA mouse study also linked lipid imbalance in lung immune cells to pulmonary fibrosis.
Phage protein study reveals how Sgl PP7 blocks bacterial target
A NAIST team found bacteriophage protein Sgl PP7 blocks MurJ, a bacterial lipid transporter needed for cell wall building, by stabilizing an outward-facing conformation. Using cryo-electron microscopy and other experiments, researchers showed Sgl PP7 inserts a short tail into a deep cavity in MurJ and prevents its transport cycle. Comparisons with phage proteins suggest different binders can use a similar strategy, pointing to future antibiotics.
DNA methylation patterns may predict MDS treatment response
A multicenter study found DNA methylation patterns at diagnosis can help predict which myelodysplastic syndrome patients will respond to azacitidine. Researchers at Sylvester Comprehensive Cancer Center analyzed mutations, chemical marks and gene activity in 98 patients and found methylation was more useful than gene activity alone. The model could support more personalized treatment choices, though further research is needed.
UCLA mouse study links lipid imbalance to pulmonary fibrosis
A UCLA Health study in mice found lipid dysregulation in alveolar macrophages can trigger pulmonary fibrosis. Mice lacking ABCG1 protein accumulated cholesterol in these immune cells before lung changes, and the lipids signaled fibroblasts to make scar tissue. Restoring normal macrophage lipid handling through bone marrow transplantation almost completely protected mice.
Rutgers wins $2.9 million grant to study youth overdoses
Rutgers researchers will use a $2.9 million NIH grant to study drug overdose trends among adolescents and young adults over five years. The team will analyze national Medicaid data for ages 12 to 29 who had an overdose since 2016, examining overdose types, follow-up treatments and whether care reduces repeat overdoses and death. The study aims to identify gaps after nonfatal overdoses in an evolving drug environment.
Australian MND therapy NUN-004 advances to Phase 2 trial
Australian-developed protein therapy NUN-004, from UQ QBI and NuNerve, will enter a national Phase 2 trial with 75 participants at six Australian sites. It aims to inhibit the EphA4 receptor to halt or reverse MND progression, not just slow decline. The trial will assess function, safety, respiratory, neurophysiological, quality-of-life and biomarker measures.
Illustration 
